Full Course Description

Psychedelics, Hallucinogens and Entheogens: What Clinicians Need to Know

Program Information

Objectives

Analyze known mechanisms of action for psychedelics, MDMA, and dissociatives as they relate to case conceptualization.
Evaluate recent clinical trials, other research on psychedelics, and their treatment implications.
Determine contraindications to using psychedelics in therapy, as well as other potential risks of use.
Appraise the basic concepts of psychedelic integration as related to clinical treatment.
Utilize clinical strategies to talk about psychedelics when your clients bring up their experiences in session.
Analyze the ethical challenges that may arise when discussing use of psychedelics in session.

Copyright : 15/07/2020

Psychedelics in Therapy: New Ways to Catalyze Healing

Program Information

Objectives

Evaluate the results of clinical trials of MDMA-assisted psychotherapy for PTSD and their treatment implications.
Determine the clinical uses of MDMA-assisted psychotherapy in the treatment of trauma.
Appraise the role therapists play in the sessions while the client is under the effects of these drugs, and how to facilitate the talk-therapy sessions that precede and follow it to improve client outcomes.
Assess the risks and limitations of MDMA and psilocybin-assisted psychotherapy.

Copyright : 12/01/2021

MDMA-Assisted Psychotherapy & Ecstasy: Cutting-Edge Research, Assessment & Intervention for Trauma, Anxiety & More

Program Information

Objectives

Appraise recent clinical trials and other research done with MDMA as it relates to clinical practice.
Evaluate contraindications to using MDMA and other potential risks of use as related to clinical treatment.
Analyze legal and ethical considerations of MDMA-assisted therapy as it relates to clinical practice.
Evaluate the scientific research of how MDMA works in the brain and the body for a better understanding relating to client outcomes.

Copyright : 29/09/2020

Psychedelics in Modern Healing

Today there’s growing interest in the use of psychedelic substances, once considered therapeutically off-limits, in the clinical treatment of PTSD, depression, addictions, and a range of other conditions.

The principles on which these healing pathways are based have been shown to be validated by psychoneuroimmunology and interpersonal neurobiology.

This workshop recording will look at the distinctive experiences of both clients and therapists that psychedelics can facilitate.

Program Information

Objectives

Appraise the differences among various psychedelic substances and their potential uses in a therapeutic setting.
Investigate the process of introducing and preparing for a psychedelic-based session with clients.
Assess how to integrate what has been experienced and learned in a psychedelic journey after the session.

Psychedelic-Assisted Therapy: The Psychotherapy Whose Time Has Come

The need for more effective treatments of mental health issues is a nationally recognized challenge in psychiatry and psychology. Research findings strongly support the efficacy of psychedelic medicines for several clinical symptomologies and clinical trials are underway in the US, UK and EU that will likely result in the availability of MDMA and psilocybin for legal use in US medical clinics for PTSD and depression, respectively, within 2 to 4 years. Within the next several years there is a national need to train medical and mental health professionals who wish to be ready to conduct psychedelic-assisted psychotherapy.

This recording will begin with a review of the clinical research outcomes on psychedelic-assisted therapy for depression, anxiety, PTSD, end-of-life distress, and substance abuse. We will discuss the professional training being done by the Multidisciplinary Association of Psychedelic Studies (MAPS) and the California Institute of Integral Studies (CIIS). The recording will offer some of the teachings from the CIIS professional training program, which includes neuropharmacology and research foundations, global transformational traditions, mindfulness practices, therapist competencies, and en vivo instruction. An engaging discussion will follow the presentation on questions about the place for such training for licensed psychotherapists and medical professionals, the future of the research, and where psychedelics fit within the newest innovations in the mental health field.

Program Information

Objectives

Appraise research related to psychedelic-assisted therapy and efficacy across diagnostic categories.
Evaluate the growing utilization of mental health professionals in the use of psychedelic-assisted therapies.
Investigate the neurobiological underpinnings of psychedelic facilitation of psychotherapy.